S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

KRON Kronos Bio Inc

0.9699

0.1049 (12.13%)

Nov 27 2024 - Closed

Delayed by 15 minutes

California Biotech Stock Bid Up Prior To Opening Bell On Major Announcement

A California-based biotech company is already stealing the show during Wednesday’s premarket after the company announced a CEO transition and an estimated 83% reduction in...

To read the full story on AllPennyStocks.com, click here.

Kronos Bio (NASDAQ:KRON)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Kronos Bio Charts.

Kronos Bio (NASDAQ:KRON)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Kronos Bio Charts.

Kronos Bio Inc News

California Biotech Stock Bid Up Prior To Opening Bell On Major Announcement
Wednesday 27 November 2024 (2 days ago) • AllPennyStocks.com

Kronos Bio Announces CEO Transition and Reduction in Force
Wednesday 27 November 2024 (2 days ago) • GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness
Thursday 14 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
Thursday 14 November 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Wednesday 13 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
Wednesday 13 November 2024 (2 weeks ago) • GlobeNewswire Inc.

Form S-3 - Registration statement under Securities Act of 1933
Thursday 7 November 2024 (3 weeks ago) • Edgar (US Regulatory)

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma
Tuesday 5 November 2024 (3 weeks ago) • GlobeNewswire Inc.

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
Wednesday 23 October 2024 (1 month ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 15 October 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 15 October 2024 (1 month ago) • Edgar (US Regulatory)

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
Wednesday 9 October 2024 (2 months ago) • GlobeNewswire Inc.

More Kronos Bio Inc News Articles

North Bay Resources (PK)

ERHC Energy (CE)

Kraig Biocraft Laborator... (QB)

Anavex Life Sciences

Northwest Biotherapeutics (QB)

Bioelectronics (PK)

Intergrated Cannabis Sol... (PK)

Digital Brand Media and ... (PK)

Elite Pharmaceuticals (QB)

Lightwave Logic

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions